Compare Organon & Co. Common Stock (OGN) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Xpeng Inc - ADR — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Xpeng Inc - ADR trades at $9.44 (market cap $9.24B). The key difference: Xpeng Inc - ADR is far larger — about 2.6× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Xpeng Inc - ADR for 81 Days on average.
| OGN | XPEV | |
|---|---|---|
Market Cap | $3.62B | $9.24B |
Volume | 2,892,999 | 6,669,510 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $28.07 |
52-Week Low | $5.70 | $9.25 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $11.04B | $11.18B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XPeng (XPEV) trades at $9.75, up 0.93% on the day, amid a bearish technical signal and mixed financial performance. The company reported strong revenue growth to $76.72 billion in 2025 (XPeng earnings report, 2025) but continues to post net losses, with a negative net income margin of -4.14%. Recent news highlights expansion into AI and robotics, including the launch of the G9L SUV and humanoid robot production, signaling strategic diversification beyond electric vehicles.
The investment outlook balances high growth potential against persistent profitability challenges. Analyst consensus is bullish with a $17.55 price target (MarketBeat, 2026), but risks include intense EV competition, macroeconomic pressures in China, and the capital-intensive nature of new technology ventures. Shareholder value hinges on achieving sustained profitability and successful execution of its Physical AI initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
